Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) – HC Wainwright cut their Q2 2026 earnings estimates for shares of Phio Pharmaceuticals in a research report issued on Friday, May 8th. HC Wainwright analyst M. Keller now expects that the company will earn ($0.35) per share for the quarter, down from their prior forecast of ($0.23). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.40) EPS and FY2027 earnings at ($0.63) EPS.
Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10).
Get Our Latest Report on Phio Pharmaceuticals
Phio Pharmaceuticals Stock Performance
NASDAQ:PHIO opened at $1.08 on Tuesday. The firm’s fifty day moving average is $1.21 and its 200-day moving average is $1.25. Phio Pharmaceuticals has a 52 week low of $0.81 and a 52 week high of $4.19. The firm has a market cap of $12.55 million, a P/E ratio of -0.74 and a beta of 0.84.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Phio Pharmaceuticals stock. Cetera Investment Advisers increased its stake in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) by 26.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,500 shares of the company’s stock after acquiring an additional 9,000 shares during the quarter. Cetera Investment Advisers owned approximately 0.39% of Phio Pharmaceuticals worth $45,000 at the end of the most recent quarter. Institutional investors own 57.31% of the company’s stock.
About Phio Pharmaceuticals
Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.
Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.
Featured Stories
- Five stocks we like better than Phio Pharmaceuticals
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
